Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 1,307 trials

Allopurinol for Brain Protection in Newborns with Heart Disease

We are studying whether allopurinol can help reduce brain injury in newborns with critical congenital heart disease during and after cardiac surgery. This trial will also assess its effects on brain and heart function, as well as overall development.

Brain Injury in Neonates with Congenital Heart Disease>2 yearsConfirmation phase (III)Standard MedicinesCardiologyNeurologyPediatrics

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Metastatic Non-Small Cell Lung Cancer: Ivonescimab vs Pembrolizumab

We are studying whether ivonescimab combined with chemotherapy helps patients with metastatic non-small cell lung cancer live longer and manage their disease better than pembrolizumab with chemotherapy.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Outpatient Surgery: Dexmedetomidine Study

We are examining how dexmedetomidine affects blood flow and heart function in patients undergoing scheduled outpatient surgery. This research may help improve anesthesia practices.

Induction of Anesthesia>2 yearsConfirmation phase (III)Internal MedicineOtolaryngology

Vaginal Progesterone for Fertility: Standard vs. New Formulation

We are comparing two formulations of vaginal progesterone to see which one better supports pregnancy in women undergoing fertility treatments. This study aims to improve pregnancy rates and assess safety for participants.

Infertility>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Oxygen Management During Anesthesia: The LOWOX Trial

We are studying whether a tailored approach to oxygen levels during anesthesia improves recovery and oxygen levels after surgery compared to standard fixed oxygen use. This trial involves patients undergoing various surgical procedures.

Surgery under General Anesthesia3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Hypochondroplasia: Vosoritide Treatment Study

We are testing a new medication, vosoritide, to see if it helps children with hypochondroplasia grow taller compared to a placebo. The study aims to evaluate its effects on growth velocity and height.

Hypochondroplasia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatrics

Botulinum Toxin for Spastic Equinovarus in Stroke Patients

We are exploring how a treatment with botulinum toxin type A affects muscle and nerve properties in people who have had their first stroke. This study aims to gather insights that could improve future treatments for spastic equinovarus.

Spastic Equinovarus in Stroke Patients3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Multiple Sclerosis: Personalized Ocrelizumab Treatment

We are studying whether a tailored dosing of ocrelizumab is as effective as the standard treatment in managing relapsing remitting multiple sclerosis. This trial aims to improve treatment personalization for better disease control.

Multiple Sclerosis>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurology

Asthma Treatment: Tezepelumab Study

We are investigating whether tezepelumab can improve airway structure and function in patients with asthma compared to a placebo. This study will also explore its effects on lung health and asthma flare-ups.

Severe Asthma3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementAllergologyPulmonology

Severe Influenza: Dexamethasone vs. Placebo

We are studying whether dexamethasone can help patients with severe influenza recover better than a placebo. The trial will assess hospitalization rates, safety, and other health impacts.

H1N1 Influenza>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Spontaneous Urticaria: Barzolvolimab Study

We are investigating whether barzolvolimab can help patients with chronic spontaneous urticaria who still experience symptoms despite antihistamine treatment. The study aims to see if it reduces itching and hives compared to a placebo.

Chronic Spontaneous Urticaria1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementAllergologyDermatology

Cariprazine for Adolescents with Schizophrenia

We are studying the safety and tolerability of cariprazine in adolescents aged 13 to under 18 with schizophrenia. This trial aims to see how well the medication works and its impact on health-related outcomes.

Schizophrenia>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsPsychiatry

Vertebral Metastases: Zoledronic Acid or Denosumab with Radiation

We are studying whether adding zoledronic acid or denosumab to stereotactic radiotherapy improves treatment outcomes for patients with vertebral metastases. This trial will also look at cost-effectiveness and various health impacts.

Metastatic Bone Pain>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Hormonal Treatment for Adolescents with Gender Dysphoria

We are studying the effects of starting hormonal treatment at age 14 on the well-being of adolescents with gender dysphoria. This research aims to assess both the effectiveness and safety of the treatment as they transition into adulthood.

Gender Dysphoria>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyPsychiatry

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology